Product Code: GVR-1-68038-096-5
Transcatheter Heart Valve Market Growth & Trends:
The global transcatheter heart valve market size is anticipated to reach a value of USD 13.0 billion by 2030, registering at a CAGR of 15.2% from 2023 to 2030,according to a new report by Grand View Research, Inc. The market is currently under-penetrated as these products are approved only for geriatric patients who cannot undergo normal valve surgeries. Growth drivers such as increasing prevalence of chronic cardiovascular diseases, increasing economic development, improvement in reimbursement scenario, and faster adoption of new technologies are expected to significantly improve the usage rates over the forecast period.
The transcatheter heart valve market is evolving rapidly due to the continuous investments in R&D by the key market players such as Edwards Life Sciences, Medtronic, St. Jude, and Boston Scientific. The technologically advanced products such as the SAPIEN 3 transcatheter heart valve and the TRINITY Valve are designed to reduce the surgical complications and improve patient compliance. For instance, the TRINITY TAVI system enables easy retrieval and repositioning of the device, without compromising on patient safety and treatment outcomes.
Furthermore, the market is expected to experience strong tailwinds on account of growing investor interest, lucrative product pipeline, faster regulatory approvals, and high competition to acquire potential start-ups. For example, some of the notable investments in the market include the USD 37 million funding of Venus MedTech by Goldman Sachs. In line with the market trends, the other market participants such as Boston Scientific, Edward Life Sciences, and Medtronic have also increased their investments to develop new products for management of mitral valve regurgitation and tricuspid valve replacements.
Transcatheter Heart Valve Market Report Highlights:
- Aortic stenosis is the most prevalent valve disease, and if untreated it can lead to death. The transcatheter aortic valve segment accounted for the largest market share of 84.55% in 2022.
- However, the transcatheter mitral valve segment is expected to have the highest CAGR of 23.0% over the forecast period. The U.S. FDA approval of the transcatheter mitral repair device in October 2013 is a key driver of the growth of this segment.
- North America held the maximum share of nearly 48.4% in 2022. A combination of different factors such as the presence of large target population, high disposable income, strong reimbursement framework, contribute toward the high revenue generated in this region.
- Asia Pacific is anticipated to register the fastest CAGR over the forecast period. Increasing disease burden, improvement in clinical trial regulations, growing preference for advanced medical technologies, increase in medical tourism, and special incentives for investments in healthcare sector are expected to strongly favor the growth in this region.
Table of Contents
Chapter 1. Methodology and Scope
- 1.1. Market Segmentation & Scope
- 1.1.1. Application
- 1.1.2. Technology
- 1.1.3. Regional scope
- 1.1.4. Estimates and forecast timeline
- 1.2. Research Methodology
- 1.3. Information Procurement
- 1.3.1. Purchased database
- 1.3.2. GVR's internal database
- 1.3.3. Secondary sources
- 1.3.4. Primary research
- 1.3.5. Details of primary research
- 1.4. Information or Data Analysis
- 1.5. Market Formulation & Validation
- 1.6. Model Details
- 1.7. List of Secondary Sources
- 1.8. List of Primary Sources
- 1.9. Objectives
Chapter 2. Executive Summary
- 2.1. Market Outlook
- 2.2. Segment Outlook
- 2.2.1. Application outlook
- 2.2.2. Technology outlook
- 2.2.3. Regional outlook
- 2.3. Competitive Insights
Chapter 3. Transcatheter Heart Valve Market Variables; Trends & Scope
- 3.1. Market Lineage Outlook
- 3.1.1. Parent market outlook
- 3.1.2. Related/ancillary market outlook
- 3.2. Penetration & Growth Prospect Mapping
- 3.3. Market Dynamics
- 3.3.1. Market driver analysis
- 3.3.2. Market restraint analysis
- 3.4. Transcatheter Heart Valve Market Analysis Tools
- 3.4.1. Industry Analysis - Porter's
- 3.4.1.1. Supplier power
- 3.4.1.2. Buyer power
- 3.4.1.3. Substitution threat
- 3.4.1.4. Threat of new entrant
- 3.4.1.5. Competitive rivalry
- 3.4.2. PESTEL Analysis
- 3.4.2.1. Political landscape
- 3.4.2.2. Technological landscape
- 3.4.2.3. Economic landscape
Chapter 4. Transcatheter Heart Valve Market: Application Estimates & Trend Analysis
- 4.1. Transcatheter Heart Valve Market: Key Takeaways
- 4.2. Transcatheter Heart Valve Market: Movement & Market Share Analysis; 2022 & 2030
- 4.3. Transcatheter Aortic Valve
- 4.3.1. Transcatheter aortic valve market estimates and forecasts; 2018 to 2030 (USD Million)
- 4.4. Transcatheter Pulmonary Valve
- 4.4.1. Transcatheter pulmonary valve market estimates and forecasts; 2018 to 2030 (USD Million)
- 4.5. Transcatheter Mitral Valve
- 4.5.1. Transcatheter mitral valve market estimates and forecasts; 2018 to 2030 (USD Million)
Chapter 5. Transcatheter Heart Valve Market: Technology Estimates & Trend Analysis
- 5.1. Transcatheter Heart Valve Market: Key Takeaways
- 5.2. Transcatheter Heart Valve Market: Movement & Market Share Analysis; 2022 & 2030
- 5.3. Balloon Expanded Transcatheter Valve
- 5.3.1. Balloon expanded transcatheter valve market estimates and forecasts; 2018 to 2030 (USD Million)
- 5.4. Self-Expanded Transcatheter Valve
- 5.4.1. Self-expanded transcatheter valve delivery market estimates and forecasts; 2018 to 2030 (USD Million)
Chapter 6. Transcatheter Heart Valve Market: Regional Estimates & Trend Analysis
- 6.1. Regional Outlook
- 6.2. Transcatheter Heart Valve Market by Region: Key Takeaway
- 6.3. North America
- 6.3.1. Market estimates and forecasts; 2018 - 2030 (Revenue; USD Million)
- 6.3.2. U.S.
- 6.3.2.1. Market estimates and forecasts; 2018 - 2030 (Revenue; USD Million)
- 6.3.3. Canada
- 6.3.3.1. Market estimates and forecasts; 2018 - 2030 (Revenue; USD Million)
- 6.4. Europe
- 6.4.1. UK
- 6.4.1.1. Market estimates and forecasts; 2018 - 2030 (Revenue; USD Million)
- 6.4.2. Germany
- 6.4.2.1. Market estimates and forecasts; 2018 - 2030 (Revenue; USD Million)
- 6.4.3. France
- 6.4.3.1. Market estimates and forecasts; 2018 - 2030 (Revenue; USD Million)
- 6.4.4. Italy
- 6.4.4.1. Market estimates and forecasts; 2018 - 2030 (Revenue; USD Million)
- 6.4.5. Spain
- 6.4.5.1. Market estimates and forecasts; 2018 - 2030 (Revenue; USD Million)
- 6.4.6. Sweden
- 6.4.6.1. Market estimates and forecasts; 2018 - 2030 (Revenue; USD Million)
- 6.4.7. Norway
- 6.4.7.1. Market estimates and forecasts; 2018 - 2030 (Revenue; USD Million)
- 6.4.8. Denmark
- 6.4.8.1. Market estimates and forecasts; 2018 - 2030 (Revenue; USD Million)
- 6.5. Asia Pacific
- 6.5.1. Japan
- 6.5.1.1. Market estimates and forecasts; 2018 - 2030 (Revenue; USD Million)
- 6.5.2. China
- 6.5.2.1. Market estimates and forecasts; 2018 - 2030 (Revenue; USD Million)
- 6.5.3. India
- 6.5.3.1. Market estimates and forecasts; 2018 - 2030 (Revenue; USD Million)
- 6.5.4. Australia
- 6.5.4.1. Market estimates and forecasts; 2018 - 2030 (Revenue; USD Million)
- 6.5.5. Thailand
- 6.5.5.1. Market estimates and forecasts; 2018 - 2030 (Revenue; USD Million)
- 6.5.6. South Korea
- 6.5.6.1. Market estimates and forecasts; 2018 - 2030 (Revenue; USD Million)
- 6.6. Latin America
- 6.6.1. Brazil
- 6.6.1.1. Market estimates and forecasts; 2018 - 2030 (Revenue; USD Million)
- 6.6.2. Mexico
- 6.6.2.1. Market estimates and forecasts; 2018 - 2030 (Revenue; USD Million)
- 6.6.3. Argentina
- 6.6.3.1. Market estimates and forecasts; 2018 - 2030 (Revenue; USD Million)
- 6.7. MEA
- 6.7.1. Saudi Arabia
- 6.7.1.1. Market estimates and forecasts; 2018 - 2030 (Revenue; USD Million)
- 6.7.2. South Africa
- 6.7.2.1. Market estimates and forecasts; 2018 - 2030 (Revenue; USD Million)
- 6.7.3. UAE
- 6.7.3.1. Market estimates and forecasts; 2018 - 2030 (Revenue; USD Million)
- 6.7.4. Kuwait
- 6.7.4.1. Market estimates and forecasts; 2018 - 2030 (Revenue; USD Million)
Chapter 7. Competitive Landscape
- 7.1. Recent Developments & Impact Analysis; By Key Market Participants
- 7.2. Market Participant Categorization
- 7.2.1. Boston Scientific Corporation
- 7.2.1.1. Company overview
- 7.2.1.2. Financial performance
- 7.2.1.3. Product benchmarking
- 7.2.1.4. Strategic initiatives
- 7.2.2. Bracco Group
- 7.2.2.1. Company overview
- 7.2.2.2. Financial performance
- 7.2.2.3. Product benchmarking
- 7.2.2.4. Strategic initiatives
- 7.2.3. Braile Biomedica
- 7.2.3.1. Company overview
- 7.2.3.2. Financial performance
- 7.2.3.3. Product benchmarking
- 7.2.3.4. Strategic initiatives
- 7.2.4. Direct Flow Medical
- 7.2.4.1. Company overview
- 7.2.4.2. Financial performance
- 7.2.4.3. Product benchmarking
- 7.2.4.4. Strategic initiatives
- 7.2.5. Edwards Lifesciences
- 7.2.5.1. Company overview
- 7.2.5.2. Financial performance
- 7.2.5.3. Product benchmarking
- 7.2.5.4. Strategic initiatives
- 7.2.6. JenaValve, St. Jude Medical
- 7.2.6.1. Company overview
- 7.2.6.2. Financial performance
- 7.2.6.3. Product benchmarking
- 7.2.6.4. Strategic initiatives
- 7.2.7. Symetis
- 7.2.7.1. Company overview
- 7.2.7.2. Financial performance
- 7.2.7.3. Product benchmarking
- 7.2.7.4. Strategic initiatives
- 7.2.8. ValveXchange, Inc
- 7.2.8.1. Company overview
- 7.2.8.2. Financial performance
- 7.2.8.3. Product benchmarking
- 7.2.8.4. Strategic initiatives